## Founding Date | 2011 |

Ignyta is a subsidiary of Roche

USD | FY, 2013 | Y, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|---|

## Revenue | 150.0k | ||||

| (100%) | ||||

## R&D expense | 10.2m | 30.5m | 73.5m | 76.9m | |

## General and administrative expense | 3.7m | 9.5m | 17.1m | 23.8m | |

## Operating expense total | 13.9m | 40.0m | 90.6m | 100.7m | |

## EBIT | (13.9m) | (13.9m) | (39.8m) | (90.6m) | (100.7m) |

| (26566%) | ||||

## Interest expense | 309.7k | 203.8k | 141.6k | 1.9m | 3.0m |

## Interest income | 955.0k | ||||

## Pre tax profit | (14.2m) | (14.2m) | (40.0m) | ||

## Income tax expense | 2.1k | 2.1k | 12.3k | ||

## Net Income | (14.2m) | (14.2m) | (40.0m) | (92.5m) | (103.6m) |

USD | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 150.0k | ||||||||||||||

## R&D expense | 2.2m | 3.6m | 8.6m | 20.2m | 8.8m | 10.4m | 19.8m | 20.0m | 16.6m | 34.0m | 22.2m | 21.7m | |||

## General and administrative expense | 1.8m | 2.0m | 2.2m | 3.0m | 3.9m | 3.9m | 5.2m | 5.5m | 6.1m | 5.6m | 5.5m | 6.5m | |||

## Operating expense total | 3.9m | 5.6m | 10.8m | 23.2m | 12.7m | 14.3m | 25.0m | 25.5m | 22.8m | 39.6m | 27.7m | 28.2m | |||

## EBIT | (3.4k) | (42.6k) | (3.9m) | (5.5m) | (10.8m) | (23.2m) | (12.7m) | (14.3m) | (25.0m) | (25.5m) | (22.8m) | (39.6m) | (27.7m) | (28.2m) | |

| (3643%) | ||||||||||||||

## Interest expense | 4.0 | 104.0 | 182.0 | 135.6k | 67.6k | 111.8k | 266.9k | 468.6k | 332.0k | 484.0k | 1.1m | 518.0k | 544.0k | 610.0k | 393.0k |

## Interest income | 364.0k | 296.0k | 268.0k | 219.0k | 460.0k | ||||||||||

## Pre tax profit | (4.1m) | (5.4m) | (10.7m) | ||||||||||||

## Income tax expense | 5.3k | ||||||||||||||

## Net Income | (4.0k) | (3.6k) | (42.8k) | (4.1m) | (5.4m) | (10.7m) | (23.5m) | (13.1m) | (14.6m) | (25.5m) | (26.6m) | (23.3m) | (40.2m) | (28.3m) | (28.6m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 51.8m | 6.3m | 46.4m | 24.3m |

## Accounts Receivable | ||||

## Prepaid Expenses | 671.4k | 1.7m | 4.4m | |

## Inventories | ||||

## Current Assets | 52.5m | 71.3m | 136.2m | 111.9m |

## PP&E | 830.7k | 6.3m | 18.8m | 6.3m |

## Total Assets | 53.3m | 85.3m | 196.1m | 144.9m |

## Accounts Payable | 811.6k | 975.3k | 3.8m | 13.5m |

## Short-term debt | 1.4m | 6.9k | ||

## Current Liabilities | 1.5m | 7.5m | 24.8m | 17.5m |

## Long-term debt | 19.0m | 21.0m | 31.0k | |

## Total Debt | 22.4m | |||

## Total Liabilities | 11.5m | 29.4m | 60.2m | 50.1m |

## Common Stock | 139.0 | 2.0k | 3.0k | |

## Additional Paid-in Capital | 57.4m | 111.6m | 284.3m | 346.5m |

## Retained Earnings | (148.0m) | (251.7m) | ||

## Total Equity | 41.8m | 55.9m | 136.0m | 94.8m |

## Financial Leverage | 1.3 x | 1.5 x | 1.4 x | 1.5 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | (14.2m) | (40.0m) | (92.5m) | (103.6m) |

## Depreciation and Amortization | 112.4k | 1.4m | 3.4m | 3.5m |

## Accounts Payable | 519.6k | 163.7k | 2.9m | 95.0k |

## Cash From Operating Activities | (13.1m) | (32.5m) | (50.8m) | (90.1m) |

## Purchases of PP&E | (688.0k) | (3.1m) | (3.5m) | (2.5m) |

## Cash From Investing Activities | (678.0k) | (74.3m) | (61.0m) | 14.3m |

## Short-term Borrowings | (1.5m) | (10.0m) | (17.4m) | |

## Long-term Borrowings | (22.6k) | (172.0k) | ||

## Cash From Financing Activities | 60.5m | 61.4m | 151.8m | 53.8m |

## Net Change in Cash | 46.8m | (45.5m) | 40.0m | (22.0m) |

## Interest Paid | 51.1k | 1.9m | 2.5m | 2.6m |

## Income Taxes Paid | 2.1k | 5.3k |

USD | Q1, 2013 |
---|---|

## Financial Leverage | -0.1 x |